This is not the most recent version of the article. View current version (28 JAN 2015)

Diagnostic Test Accuracy Protocol

You have free access to this content

The accuracy of 18FDG-PET in the early diagnosis of Alzheimer’s disease dementia and other dementias in people with MCI

  1. Marco Vacante1,*,
  2. Nadja Smailagic2,
  3. Christos Sachpekidis3,
  4. Chris Hyde4,
  5. Steven Martin2,
  6. Obioha Ukoumunne5

Editorial Group: Cochrane Dementia and Cognitive Improvement Group

Published Online: 5 JUL 2013

DOI: 10.1002/14651858.CD010632


How to Cite

Vacante M, Smailagic N, Sachpekidis C, Hyde C, Martin S, Ukoumunne O. The accuracy of 18FDG-PET in the early diagnosis of Alzheimer’s disease dementia and other dementias in people with MCI (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD010632. DOI: 10.1002/14651858.CD010632.

Author Information

  1. 1

    University of Oxford, John Radcliffe Hospital, Nuffield Department of Medicine - OPTIMA, Oxford, Oxfordshire, UK

  2. 2

    University of Cambridge, Institute of Public Health, Cambridge, UK

  3. 3

    German Cancer Research Center, Medical PET Group - Biological Imaging, Clinical Cooperation Unit Nuclear Medicine, Heidelberg, Germany

  4. 4

    University of Exeter Medical School, University of Exeter, Peninsula Technology Assessment Group (PenTAG), Exeter, UK

  5. 5

    University of Exeter Medical School, University of Exeter, PenCLAHRC, Exeter, Devon, UK

*Marco Vacante, Nuffield Department of Medicine - OPTIMA, University of Oxford, John Radcliffe Hospital, Headly Way, Headington, Oxford, Oxfordshire, OX3 9DU, UK. marcovacante@yahoo.it.

Publication History

  1. Publication Status: New
  2. Published Online: 5 JUL 2013

SEARCH

This is not the most recent version of the article. View current version (28 JAN 2015)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

  • To determine the diagnostic accuracy of the 18F-FDG-PET index test for detecting people with MCI at baseline who would clinically convert to Alzheimer’s disease or other forms of dementia at follow-up.

  • To investigate heterogeneity of test accuracy in the included studies.

We expect that heterogeneity will be likely and that it will be an important component of the review. The potential sources of heterogeneity, which will be used as a framework for the investigation of heterogeneity, include target population, index test, target disorder and study quality and are detailed in the analysis section.